We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 02, 2021

Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed CAR T-Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study
Lancet 2021 Jun 24;[EPub Ahead of Print], JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, AK Stewart, P Hari, M Htut, A Lesokhin, A Deol, NC Munshi, E O'Donnell, D Avigan, I Singh, E Zudaire, TM Yeh, AJ Allred, Y Olyslager, A Banerjee, CC Jackson, JD Goldberg, JM Schecter, W Deraedt, SH Zhuang, J Infante, D Geng, X Wu, MJ Carrasco-Alfonso, M Akram, F Hossain, S Rizvi, F Fan, Y Lin, T Martin, S Jagannath

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading